NSV 2018 New Horizons
SlowingNew York, NYBiotechnology, PharmaceuticalsLast fund filed 2018
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| NSV 2018 New Horizons Fund | 2018 | $100M | $6.4M | 25 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Somu Subramaniam | Slowing | Aerospace & defense, Biotech & pharma, Medical devices | 13 | 1 |
| Thomas Lavin | Quiet | Digital health, Aerospace & defense, Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of NSV 2018 New Horizons’s own portfolio companies, based on 16 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of NSV 2018 New Horizons’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Bridge Street | 2 | ACUITY LINK, SVELTE MEDICAL SYSTEMS |
| Nexeption Capital | 2 | Alexar Therapeutics, Light Sciences Oncology |
| Khosla Ventures | 1 | Glydways |
| Pivotal bioVenture Partners | 1 | Light Sciences Oncology |
A shared board seat: a company where filings name a NSV 2018 New Horizons partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.